{"entity":{"id":"aglatimagene-besadenovec","kind":"drug","name":"Aglatimagene besadenovec","aka":["AdV-tk"],"tldr":"Aglatimagene besadenovec is an experimental gene therapy from Candel Therapeutics in phase 3 trials for non-small-cell lung cancer and prostate cancer, with its target not yet stated publicly.","summary":"Aglatimagene besadenovec (CAN-2409) is a gene therapy developed by Candel Therapeutics. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. The sponsor states: An adenovirus-based immunotherapy (AdV-tk/CAN-2409) that blocks DNA synthesis in dividing tumour cells, causing tumour cell death, while adenovirus capsid proteins attract immune cells to the tumour microenvironment so activated immune cells can then attack distant metastases. ClinicalTrials.gov describes the intervention as: Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first follo. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07660094 (Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)), in non-small-cell lung cancer and prostate cancer. The largest, NCT07660094, plans to enrol 500 participants with primary completion expected 2031-10-22. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Aglatimagene besadenovec","url":"https://clinicaltrials.gov/search?intr=CAN-2409"},{"label":"Sponsor pipeline page","url":"https://www.candeltx.com/pipeline/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["candel-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["aurora","nct01436968","nct02768363","nct07332000","nct04495153"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"CAN-2409","modality":"gene therapy","mechanism":"An adenovirus-based immunotherapy (AdV-tk/CAN-2409) that blocks DNA synthesis in dividing tumour cells, causing tumour cell death, while adenovirus capsid proteins attract immune cells to the tumour microenvironment so activated immune cells can then attack distant metastases.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/aglatimagene-besadenovec/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"candel-therapeutics","kind":"company","name":"Candel Therapeutics","route":"/companies/candel-therapeutics/"}],"trial":[{"id":"nct07332000","kind":"trial","name":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","route":"/trials/nct07332000/"},{"id":"aurora","kind":"trial","name":"Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)","route":"/trials/aurora/"},{"id":"nct04495153","kind":"trial","name":"CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC","route":"/trials/nct04495153/"},{"id":"nct01436968","kind":"trial","name":"Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer","route":"/trials/nct01436968/"},{"id":"nct02768363","kind":"trial","name":"Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)","route":"/trials/nct02768363/"}],"technology":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"}]}}